{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:57Z","timestamp":1786982757944,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40259-025-00716-2","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T06:14:59Z","timestamp":1743833699000},"page":"499-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Frequency of Biological Drug Use in Older Patients with Immune-Mediated Inflammatory Diseases: Results from the Large-Scale Italian VALORE Distributed Database Network"],"prefix":"10.1007","volume":"39","author":[{"given":"Federica","family":"Soardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bellitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"L\u2019Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zanforlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Scapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ledda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Ejlli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Sapigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Francesca","family":"Scarpelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Allotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano Addario","family":"Pollina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Da Cas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bucaneve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antea Maria Pia","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Senesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Spila-Alegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana Anna Maria","family":"Urru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Campomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"716_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102193","volume":"64","author":"D Wu","year":"2023","unstructured":"Wu D, Jin Y, Xing Y, Abate MD, Abbasian M, Abbasi-Kangevari M, et al. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019. EClinicalMedicine. 2023;64: 102193.","journal-title":"EClinicalMedicine."},{"key":"716_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67\u201376.","journal-title":"Drug Metab Rev"},{"key":"716_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107074","volume":"200","author":"Y Ingrasciotta","year":"2024","unstructured":"Ingrasciotta Y, Spini A, L\u2019Abbate L, Fiore ES, Carollo M, Ientile V, et al. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: an external validity analysis of 66,639 biologic users from the Italian VALORE project. Pharmacol Res. 2024;200: 107074.","journal-title":"Pharmacol Res"},{"key":"716_CR4","doi-asserted-by":"publisher","first-page":"e33559","DOI":"10.1371\/journal.pone.0033559","volume":"7","author":"C Konrat","year":"2012","unstructured":"Konrat C, Boutron I, Trinquart L, Auleley G-R, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS ONE. 2012;7:e33559.","journal-title":"PLoS ONE"},{"key":"716_CR5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","volume":"17","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1736-1743.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"716_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1203475420952423","volume":"25","author":"M Armanious","year":"2021","unstructured":"Armanious M, Vender R. A review of drug-drug interactions for biologic drugs used in the treatment of psoriasis. J Cutan Med Surg. 2021;25:38\u201344.","journal-title":"J Cutan Med Surg"},{"key":"716_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40259-021-00498-3","volume":"35","author":"G Trifir\u00f2","year":"2021","unstructured":"Trifir\u00f2 G, Isgr\u00f2 V, Ingrasciotta Y, Ientile V, L\u2019Abbate L, Foti SS, et al. Large-Scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the VALORE project. BioDrugs. 2021;35:749\u201364.","journal-title":"BioDrugs"},{"key":"716_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/CLEP.S445120","volume":"16","author":"A Spini","year":"2024","unstructured":"Spini A, L\u2019Abbate L, Ingrasciotta Y, Pellegrini G, Carollo M, Ientile V, et al. Development and validation of a META-algorithm to identify the indications of use of biological drugs approved for the treatment of immune-mediated inflammatory diseases from claims databases: insights from the VALORE project. Clin Epidemiol. 2024;16:395\u2013407.","journal-title":"Clin Epidemiol"},{"key":"716_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229973","volume":"15","author":"G Roberto","year":"2020","unstructured":"Roberto G, Spini A, Bartolini C, Moscatelli V, Barchielli A, Paoletti D, et al. Real word evidence on rituximab utilization: combining administrative and hospital-pharmacy data. PLoS ONE. 2020;15: e0229973.","journal-title":"PLoS ONE"},{"key":"716_CR10","unstructured":"European Medicines Agency (EMA). MabThera\u2014Rituximab summary of product characteristics (SmPC). 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf. Accessed 6 May 2024."},{"key":"716_CR11","unstructured":"Istituto nazionale di statistica (ISTAT). Demo\u2014demography in figure\u2014resident population by age, sex and marital status on 1st January 2024. https:\/\/www.istat.it\/. Accessed 26 Feb 2025."},{"key":"716_CR12","unstructured":"World Health Organization (WHO). Defined daily dose (DDD). 2024. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 26 Feb 2025."},{"key":"716_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semarthrit.2017.03.010","volume":"47","author":"GS Calip","year":"2017","unstructured":"Calip GS, Adimadhyam S, Xing S, Rincon JC, Lee W-J, Anguiano RH. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum. 2017;47:157\u201364.","journal-title":"Semin Arthritis Rheum"},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/apt.16923","volume":"56","author":"D Pugliese","year":"2022","unstructured":"Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56:95\u2013109.","journal-title":"Aliment Pharmacol Ther"},{"key":"716_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jbspin.2014.10.012","volume":"82","author":"C Lahaye","year":"2015","unstructured":"Lahaye C, Tatar Z, Dubost J-J, Soubrier M. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82:154\u201360.","journal-title":"Jt Bone Spine"},{"key":"716_CR16","unstructured":"Regione Emilia-Romagna\u2014Direzione generale cura della persona salute e welfare. Linee guida terapeutiche\/1-Trattamento sistemico della psoriasi cronica a placche moderata-grave con particolare riferimento ai farmaci biotecnologici. 2023. https:\/\/salute.regione.emilia-romagna.it\/ssr\/strumenti-e-informazioni\/ptr\/elaborati\/94-linee-guida-psoriasi. Accessed 26 Feb 2025."},{"key":"716_CR17","unstructured":"Regione Emilia-Romagna\u2014Direzione generale cura della persona salute e welfare. Linee guida terapeutiche\/12-Trattamento farmacologico della colite ulcerosa nell\u2019adulto con particolare riferimento ai farmaci biotecnologici. 2017. https:\/\/salute.regione.emilia-romagna.it\/ssr\/strumenti-e-informazioni\/ptr\/elaborati\/306-lg-12-colite-ulcerosa. Accessed 26 Feb 2025."},{"key":"716_CR18","unstructured":"Regione Emilia-Romagna\u2014Direzione generale sanit\u00e0 e politiche sociali. Linee guida terapeutiche\/2-Trattamento sistemico dell\u2019artrite reumatoide nell\u2019adulto con particolare riferimento ai farmaci biologici. 2014. https:\/\/salute.regione.emilia-romagna.it\/ssr\/strumenti-e-informazioni\/ptr\/elaborati\/204_LG_sintesi_artrite_reumatoide.pdf. Accessed 26 Feb 2025."},{"key":"716_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000345623","volume":"225","author":"M Esposito","year":"2012","unstructured":"Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225:312\u20139.","journal-title":"Dermatology"},{"key":"716_CR20","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/jcm10112388","volume":"10","author":"V Belleudi","year":"2021","unstructured":"Belleudi V, Rosa AC, Poggi FR, Armuzzi A, Nicastri E, Goletti D, et al. Direct and indirect impact of COVID-19 for patients with immune-mediated inflammatory diseases: a retrospective cohort study. J Clin Med. 2021;10:2388.","journal-title":"J Clin Med"},{"key":"716_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/msc.112","volume":"5","author":"GJ Treharne","year":"2007","unstructured":"Treharne GJ, Douglas KMJ, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007;5:175\u201390.","journal-title":"Musculoskeletal Care"},{"key":"716_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0897190019869158","volume":"34","author":"APM Gomides","year":"2021","unstructured":"Gomides APM, Albuquerque CP, Santos ABV, Amorim RBC, B\u00e9rtolo MB, J\u00fanior PL, et al. High levels of polypharmacy in rheumatoid arthritis\u2014a challenge not covered by current management recommendations: data from a large real-life study. J Pharm Pract. 2021;34:365\u201371.","journal-title":"J Pharm Pract"},{"key":"716_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Eng J Med. 2022;386:316\u201326.","journal-title":"N Eng J Med"},{"key":"716_CR24","unstructured":"European Medicines Agency (EMA). Janus kinase inhibitors (JAKi)\u2014referral. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Accessed 26 Feb 2025."},{"key":"716_CR25","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 27 Feb 2025."},{"key":"716_CR26","unstructured":"European Medicines Agency (EMA). Stelara - Ustekinumab summary of product characteristics (SmPC). 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf. Accessed 26 Feb 2025."},{"key":"716_CR27","unstructured":"European Medicines Agency (EMA). Entyvio\u2014vedolizumab summary of product characteristics (SmPC). 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/entyvio-epar-product-information_en.pdf. Accessed 26 Feb 2025."},{"key":"716_CR28","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.3748\/wjg.v28.i33.4823","volume":"28","author":"GD Hahn","year":"2022","unstructured":"Hahn GD, LeBlanc J-F, Golovics PA, Wetwittayakhlang P, Qatomah A, Wang A, et al. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: a retrospective study. World J Gastroenterol. 2022;28:4823\u201333.","journal-title":"World J Gastroenterol"},{"key":"716_CR29","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","volume":"18","author":"C Kapizioni","year":"2024","unstructured":"Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, et al. Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource. J Crohns Colitis. 2024;18:790\u2013800.","journal-title":"J Crohns Colitis"},{"key":"716_CR30","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1007\/s10620-021-07117-9","volume":"67","author":"R Garg","year":"2022","unstructured":"Garg R, Aggarwal M, Butler R, Achkar JP, Lashner B, Philpott J, et al. Real-world effectiveness and safety of ustekinumab in elderly Crohn\u2019s disease patients. Dig Dis Sci. 2022;67:3138\u201347.","journal-title":"Dig Dis Sci"},{"key":"716_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae174","author":"GG Gebeyehu","year":"2024","unstructured":"Gebeyehu GG, Broglio G, Liu E, Limdi JK, Selinger C, Fiske J, et al. Comparative safety and effectiveness of ustekinumab and anti-TNF in elderly Crohn\u2019s disease patients. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae174.","journal-title":"Inflamm Bowel Dis"},{"key":"716_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/jcm13020365","volume":"13","author":"T Holvoet","year":"2024","unstructured":"Holvoet T, Truyens M, De Galan C, Peeters H, Gismero FM, Elorza A, et al. Safety and effectiveness of vedolizumab and ustekinumab in elderly patients with inflammatory bowel disease: a real-life multicentric cohort study. J Clin Med. 2024;13:365.","journal-title":"J Clin Med"},{"key":"716_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11894-023-00874-9","volume":"25","author":"B Clement","year":"2023","unstructured":"Clement B, De Felice K, Afzali A. Indications and safety of newer IBD treatments in the older patient. Curr Gastroenterol Rep. 2023;25:160\u20138.","journal-title":"Curr Gastroenterol Rep"},{"key":"716_CR34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","volume":"20","author":"J Kirchgesner","year":"2022","unstructured":"Kirchgesner J, Desai RJ, Beaugerie L, Schneeweiss S, Kim SC. Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20:314-324.e16.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"716_CR35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022;20:578-590.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"716_CR36","first-page":"907","volume":"29","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Zhao R, Manceur AM, Ding Z, Kachroo S, Holiday C, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn\u2019s disease initiated on ustekinumab or adalimumab. J Manag Care Spec Pharm. 2023;29:907\u201316.","journal-title":"J Manag Care Spec Pharm"},{"key":"716_CR37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/03007995.2023.2178148","volume":"39","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Ding Z, Manceur AM, Muser E, Lefebvre P, Holiday C, et al. Treatment persistence among bio-na\u00efve patients with Crohn\u2019s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39:533\u201343.","journal-title":"Curr Med Res Opin"},{"key":"716_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12876-024-03403-8","volume":"24","author":"JE Na","year":"2024","unstructured":"Na JE, Park YE, Park J, Kim T-O, Lee JH, Park SB, et al. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-na\u00efve and bio-experienced Crohn\u2019s disease patients: a retrospective multicenter study. BMC Gastroenterol. 2024;24:306.","journal-title":"BMC Gastroenterol"},{"key":"716_CR39","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV, Limketkai BN, Haydek JP, Agrawal M, Scott FI, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307\u201343.","journal-title":"Gastroenterology"},{"key":"716_CR40","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jdv.15733","volume":"33","author":"LS van der Schoot","year":"2019","unstructured":"van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad of Dermatol Venereol. 2019;33:1913\u201320.","journal-title":"J Eur Acad of Dermatol Venereol."},{"key":"716_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1468-3083.2012.04451.x","volume":"27","author":"D B\u00f6hm","year":"2013","unstructured":"B\u00f6hm D, Stock Gissendanner S, Bangemann K, Snitjer I, Werfel T, Weyergraf A, et al. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol. 2013;27:220\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"716_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1741-7015-10-82","volume":"10","author":"N Lesuis","year":"2012","unstructured":"Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012;10:82.","journal-title":"BMC Med"},{"key":"716_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.semarthrit.2018.07.009","volume":"48","author":"DS Dalal","year":"2019","unstructured":"Dalal DS, Duran J, Brar T, Alqadi R, Halladay C, Lakhani A, et al. Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to young: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;48:799\u2013807.","journal-title":"Semin Arthritis Rheum"},{"key":"716_CR44","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.3748\/wjg.v25.i30.4158","volume":"25","author":"J-F LeBlanc","year":"2019","unstructured":"LeBlanc J-F, Wiseman D, Lakatos PL, Bessissow T. Elderly patients with inflammatory bowel disease: updated review of the therapeutic landscape. World J Gastroenterol. 2019;25:4158\u201371.","journal-title":"World J Gastroenterol"},{"key":"716_CR45","doi-asserted-by":"publisher","first-page":"232","DOI":"10.46497\/ArchRheumatol.2024.10391","volume":"39","author":"S Uslu","year":"2024","unstructured":"Uslu S, G\u00fclle S, Urak \u00d6, \u015een G, Dalk\u0131l\u0131\u00e7 E, \u015eenel S, et al. Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results. Arch Rheumatol. 2024;39:232\u201341.","journal-title":"Arch Rheumatol."},{"key":"716_CR46","unstructured":"European Medicines Agency (EMA). Remicade\u2014infliximab summary of product characteristics (SmPC). 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 27 Feb 2025."},{"key":"716_CR47","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1080\/03007995.2020.1786681","volume":"36","author":"R Roberti","year":"2020","unstructured":"Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin. 2020;36:1457\u201363.","journal-title":"Curr Med Res Opin"},{"key":"716_CR48","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/jcm9041227","volume":"9","author":"MA Barbieri","year":"2020","unstructured":"Barbieri MA, Cicala G, Cutroneo PM, Gerratana E, Palleria C, De Sarro C, et al. Safety profile of biologics used in rheumatology: an Italian prospective pharmacovigilance study. J Clin Med. 2020;9:1227.","journal-title":"J Clin Med"},{"key":"716_CR49","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.3390\/biomedicines10123280","volume":"10","author":"MA Barbieri","year":"2022","unstructured":"Barbieri MA, Viola A, Cicala G, Spina E, Fries W. Effectiveness and safety profiles of biological therapies in inflammatory bowel disease: real life data from an active pharmacovigilance project. Biomedicines. 2022;10:3280.","journal-title":"Biomedicines."},{"key":"716_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s13256-022-03625-y","volume":"16","author":"P Saha","year":"2022","unstructured":"Saha P, Srikantharajah D, Kaul A, Sofat N. Tocilizumab for relapsing and remitting giant cell arteritis: a case series. J Med Case Rep. 2022;16:389.","journal-title":"J Med Case Rep"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00716-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00716-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00716-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:26:46Z","timestamp":1745580406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00716-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00716-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"18 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Verona within the CRUI-CARE Agreement. This study was funded by the Italian Medicines Agency in the context of the multiregional pharmacovigilance project (AIFA 2012\u20132014: Post-marketing evaluation of the benefit\u2013risk profile of originator biologics and biosimilars in the dermatological, rheumatological, gastroenterological and onco-hematological areas through the establishment of a single multiregional network for the integrated analysis of data from health databases, active surveillance and clinical registers\u2014VALORE project). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G.T. participated in advisory boards and seminars as lecturer on topics not related to the paper and was sponsored by the following pharmaceutical companies in the last 2 years: Eli Lilly; Sanofi; Amgen; Novo Nordisk; Sobi; Gilead; Celgene; Daiichi Sankyo; Takeda; and MSD. He is also scientific coordinator of the pharmacoepidemiology team at the University of Verona and of the academic spin-off \u201cINSPIRE S.r.l.\u201d that in the last 2 years carried out observational studies\/systematic reviews on topics not related to the content of this article and which were funded by PTC Pharmaceutics, Kyowa Kirin, Shionogi, Shire, Chiesi, and Daiichi Sankyo. Y.I. is the CEO of the academic spin-off \u201cINSPIRE S.r.l.,\u201d which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.) and from pharmaceutical companies (Chiesi Italia, Kyowa Kirin S.r.l., Daiichi Sankyo Italia S.p.A.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available because of privacy reasons.\u00a0Requests to access the datasets should be directed and motivated to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Material (Data Transparency)"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability (Software Application or Custom Code)"}},{"value":"F.S., A.S., G.C., and G.T. contributed to the writing of the article and methodology; G.P. and C.M., contributed to the conduction of the analysis; S.A.M.U and A.C. contributed to data interpretation; C.B., L.L., Y.I., O.L., M.Z., D.A., P.S., A.C., A.S., S.L., V.B., S.L., P.C., P.R., L.E., E.S., A.P., R.F.S., G.D.S., A.A., S.A.P, R.D.C., G.B., A.M.P.M, F.B., C.S., I.S., M.T., R.G., S.S.A., and M.M. contributed to data extraction and data interpretation. All the authors reviewed the final version of the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}},{"value":"This study was conducted in the context of the multiregional active pharmacovigilance project called Post-marketing evaluation of the benefit\u2013risk profile of originator biological drugs and biosimilars in the dermatological, rheumatological, gastroenterological and onco-hematological areas through the establishment of a single multiregional network for the integrated analysis of data from health databases, active surveillance and clinical registers\u2014VALORE project, funded by the Italian Medicine Agency. The study protocol was registered in the HMA-EMA catalogue of real-world data sources and studies (EUPAS1000000211), and the ethical committees of the Academic Hospitals of Messina and Verona approved it.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approvals"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}